Idiopathic pulmonary fibrosis (IPF), once thought of as an orphan lung disease, is now a frontrunner in respiratory research. However, progress is hampered by a lack of sensitive biomarkers. Hyperpolarized xenon MR spectroscopy has demonstrated sensitivity to gas exchange in IPF and is emerging as a feasible imaging biomarker of disease. Here, we demonstrate that this methodology has high reproducibility in the disease state, correlates with clinical outcomes and demonstrates a decline in gas transfer efficiency in the lung over six months in spite of static pulmonary function test metrics.
This abstract and the presentation materials are available to members only; a login is required.